Discovery of PF-5190457, a potent, selective, and orally bioavailable ghrelin receptor inverse agonist clinical candidate
Diabetes 56 , 19511959 (2007)
( Peptide InnOvatioN for the Early diabetEs tReatment (PIONEER) trial showed that GLP-1RAs caused an overall nausea rate of 15-20% and were associated with gastrointestinal adverse events, but these were temporary and dose-dependent ( Underlying mechanism The mechanisms that contribute to the beneficial effects of SGLT2i and GLP-1RAs in patients with T2DM have been extensively studied
FODMAPs like fructose may cause unpleasant digestive symptoms, such as bloating, gas, stomach cramps, diarrhea, and constipation
While the subsequent biosynthetic reactions share similarities with those in animals, there are slight variations in the enzymes involved in the final stages
Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE (2023) Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials